Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
4.1
3.0
Journals
JPM
Special Issues
Novel Targeted Cancer Therapeutics and Personalized Medicine
share announcement

Novel Targeted Cancer Therapeutics and Personalized Medicine

A special issue of Journal of Personalized Medicine (ISSN 2075-4426). This special issue belongs to the section "Personalized Therapy and Drug Delivery".

Deadline for manuscript submissions: closed (31 December 2022) | Viewed by 5263

Special Issue Editors

Dr. Wei-Jan Wang

E-Mail Website
Guest Editor
Research Center for Cancer Biology, Department of Biological Science and Technology, China Medical University, Taichung 40604, Taiwan
Interests: cancer; molecular mechanism; drug resistance
Dr. Chih-Yang Wang

E-Mail Website
Guest Editor
Program for Cancer Molecular Biology and Drug Discovery, College of Medical Science, Taipei Medical University, Taipei 11031, Taiwan
Interests: bioinformatics; biochemistry; cancer metabolism
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Although there has been continuous improvement in the survival and other outcomes of patients with cancer over time, cancer patients still have high mortality rates. Moreover, thus far scientists have striven to develop a novel therapy based on the characteristics of numerous cancers. For instance, recent research revealed elevated immune system activity through immune checkpoint-related therapy as a novel targeted therapeutic to cure cancers. Furthermore, recent studies have indicated distinct features and heterogeneity of tumors through high throughput sequencing and mass spectrometry analysis. Therefore, it is critical to identify novel targets for cancer therapeutics and develop personalized medicine that can be used in the treatment of cancer patients. Moreover, aiming at the treatment of molecular and cellular variability under different individual cancer patients is a new direction for cancer research. In this Special Issue, the current findings, as well as future research directions on the role of novel targets, mechanisms, and specific genes of cancers will be discussed.

Dr. Wei-Jan Wang
Dr. Chih-Yang Wang
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Personalized Medicine is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • biomarkers
  • cancer
  • personalized medicine
  • novel targeted
  • genetics
  • heterogeneity
  • targeted therapy
  • pharmacogenomics

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

16 pages, 4823 KiB  
Article
Discovering Tuberosin and Villosol as Potent and Selective Inhibitors of AKT1 for Therapeutic Targeting of Oral Squamous Cell Carcinoma
by Mohd Adnan, Deeba Shamim Jairajpuri, Muskan Chaddha, Mohd Shahnawaz Khan, Dharmendra Kumar Yadav, Taj Mohammad, Abdelbaset Mohamed Elasbali, Waleed Abu Al-Soud, Salem Hussain Alharethi and Md. Imtaiyaz Hassan
J. Pers. Med. 2022, 12(7), 1083; https://doi.org/10.3390/jpm12071083 - 30 Jun 2022
Cited by 5 | Viewed by 1900
Abstract
Oral squamous cell carcinoma (OSCC) is a major cause of death in developing countries because of high tobacco consumption. RAC-alpha serine-threonine kinase (AKT1) is considered as an attractive drug target because its prolonged activation and overexpression are associated with cancer progression and metastasis. [...] Read more.
Oral squamous cell carcinoma (OSCC) is a major cause of death in developing countries because of high tobacco consumption. RAC-alpha serine-threonine kinase (AKT1) is considered as an attractive drug target because its prolonged activation and overexpression are associated with cancer progression and metastasis. In addition, several AKT1 inhibitors are being developed to control OSCC and other associated forms of cancers. We performed a screening of the IMPPAT (Indian Medicinal Plants, Phytochemistry and Therapeutics) database to discover promising AKT1 inhibitors which pass through various important filters such as ADMET (absorption, distribution, metabolism, excretion, and toxicity) properties, physicochemical properties, PAINS (pan-assay interference compounds) filters, PASS (prediction of activity spectra for substances) analysis, and specific interactions with AKT1. Molecules bearing admirable binding affinity and specificity towards AKT1 were selected for further analysis. Initially, we identified 30 natural compounds bearing appreciable affinity and specific interaction with AKT1. Finally, tuberosin and villosol were selected as potent and selective AKT1 inhibitors. To obtain deeper insights into binding mechanism and selectivity, we performed an all-atom molecular dynamics (MD) simulation and principal component analysis (PCA). We observed that both tuberosin and villosol strongly bind to AKT1, and their complexes were stable throughout the simulation trajectories. Our in-depth structure analysis suggested that tuberosin and villosol could be further exploited in the therapeutic targeting of OSCC and other cancers after further clinical validations. Full article
(This article belongs to the Special Issue Novel Targeted Cancer Therapeutics and Personalized Medicine)
►▼ Show Figures

Figure 1

15 pages, 36057 KiB  
Article
Bioinformatics Analyses Identify the Therapeutic Potential of ST8SIA6 for Colon Cancer
by Chou-Yuan Ko, Tian-Huei Chu, Ching-Cheng Hsu, Hsin-Pao Chen, Shih-Chung Huang, Chen-Lin Chang, Shiow-Jyu Tzou, Tung-Yuan Chen, Chia-Chen Lin, Pei-Chun Shih, Chung-Hsien Lin, Chuan-Fa Chang and Yung-Kuo Lee
J. Pers. Med. 2022, 12(3), 401; https://doi.org/10.3390/jpm12030401 - 4 Mar 2022
Cited by 6 | Viewed by 2745
Abstract
Sialylation of glycoproteins is modified by distinct sialyltransferases such as ST3Gal, ST6Gal, ST6GalNAc, or ST8SIA with α2,3-, α2,6-, or α2,8-linkages. Alteration of these sialyltransferases causing aberrant sialylation is associated with the progression of colon cancer. However, among the ST8- sialyltransferases, the role of [...] Read more.
Sialylation of glycoproteins is modified by distinct sialyltransferases such as ST3Gal, ST6Gal, ST6GalNAc, or ST8SIA with α2,3-, α2,6-, or α2,8-linkages. Alteration of these sialyltransferases causing aberrant sialylation is associated with the progression of colon cancer. However, among the ST8- sialyltransferases, the role of ST8SIA6 in colon cancer remains poorly understood. In this study, we explored the involvement of ST8SIA6 in colon cancer using multiple gene databases. The relationship between ST8SIA6 expression and tumor stages/grades was investigated by UALCAN analysis, and Kaplan–Meier Plotter analysis was used to analyze the expression of ST8SIA6 on the survival outcome of colon cancer patients. Moreover, the biological functions of ST8SIA6 in colon cancer were explored using LinkedOmics and cancer cell metabolism gene DB. Finally, TIMER and TISMO analyses were used to delineate ST8SIA6 levels in tumor immunity and immunotherapy responses, respectively. ST8SIA6 downregulation was associated with an advanced stage and poorly differentiated grade; however, ST8SIA6 expression did not affect the survival outcomes in patients with colon cancer. Gene ontology analysis suggested that ST8SIA6 participates in cell surface adhesion, angiogenesis, and membrane vesicle trafficking. In addition, ST8SIA6 levels affected immunocyte infiltration and immunotherapy responses in colon cancer. Collectively, these results suggest that ST8SIA6 may serve as a novel therapeutic target towards personalized medicine for colon cancer. Full article
(This article belongs to the Special Issue Novel Targeted Cancer Therapeutics and Personalized Medicine)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop